Normal view MARC view ISBD view

Somatic substitution signature as an innovative tool in lung cancer diagnosis. [electronic resource]

By:

Busca, Stéphane

Contributor(s):

Producer: 20201112Description: 14561 p. digitalISSN:

2045-2322

Subject(s):

Online resources:

Available from publisher's website

In: Scientific reports vol. 9

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

14441 Pathway-specific engagement of ephrinA5-EphA4/EphA5 system of the substantia nigra pars reticulata in cocaine-induced responses.
by Kimura, Kensuke
14442 Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease.
by Armentero, Marie-Therese
14443 Regulation of dopaminergic neuron firing by heterogeneous dopamine autoreceptors in the substantia nigra pars compacta.
by Jang, Jin Young
14444 Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
by Tatenhorst, Lars
14445 Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study.
by Bohnen, Nicolaas I
14446 Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.
by West, Andrew B
14447 Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses.
by Lofrumento, Dario D
14448 Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration.
by Hernandes, Marina S
14449 Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson's disease: Possible involvement of ERβ/Nrf2/HO-1 signaling.
by Baluchnejadmojarad, Tourandokht
14450 No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.
by Schöls, Ludger
14451 Protective effect of resveratrol against nigrostriatal pathway injury in striatum via JNK pathway.
by Li, Dan
14452 Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
by Pupyshev, Alexander B
14453 Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy.
by Zhu, Junge
14454 Moutan Cortex Radicis inhibits the nigrostriatal damage in a 6-OHDA-induced Parkinson's disease model.
by Choi, Yeong-Gon
14455 Critical Role of Oxidatively Damaged DNA in Selective Noradrenergic Vulnerability.
by Zhan, Yanqiang
14456 The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
by Jenner, P
14457 Administration of either non-NMDA receptor agonists or NMDA receptor antagonists into the substantia nigra or the globus pallidus reduces the psychostimulant effect of high helium pressure on locomotor activity in rats.
by Kriem, B
14458 Functional activity of zona incerta neurons is altered after nigrostriatal denervation in hemiparkinsonian rats.
by Périer, C
14459 Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
by Quik, M
14460 Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects.
by Ai, Yi